LONDON, May 20 (Reuters) - Some leading AstraZeneca Plc shareholders were at odds over whether the British drugmaker made the right decision in rejecting Pfizer Inc's final $118 billion bid to buy the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results